Skye Bioscience receives second Nasdaq delisting notice for failing minimum equity requirement

summarizeSummary

Skye Bioscience received a Nasdaq delisting notice for failing to meet the minimum stockholders' equity requirement, adding to its existing delisting threat for bid price.

check_boxKey Events · Corporate Governance and Compliance · SKYE

• New Nasdaq Delisting Notice

  Skye Bioscience received a notification from Nasdaq on May 13, 2026, stating it is not in compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity. The company reported $9,011,804 in stockholders' equity as of March 31, 2026.

• Compliance Deadline

  The company has 45 calendar days, until June 29, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days, until November 9, 2026.

• Compounding Delisting Threats

  This new notice follows a previous Nasdaq deficiency letter received on March 19, 2026, for failing to meet the minimum $1.00 bid price requirement. The company now faces two separate delisting threats.

• Financial Distress Context

  This notice comes after the company's Q1 2026 10-Q, filed on May 11, 2026, which reiterated a going concern warning and reported deepening losses and critical cash burn.

auto_awesomeAnalysis · SKYE · Life Sciences

This 8-K reveals a new, distinct Nasdaq delisting threat for Skye Bioscience, adding to its existing bid price deficiency. The company's stockholders' equity of $9.01 million falls below the Nasdaq Global Market's $10 million minimum. This compounds the severe financial distress highlighted in recent filings, including a going concern warning and critical cash burn. Failure to regain compliance could lead to delisting, significantly impacting liquidity and investor confidence.